News for Aquestive Therapeutics, Inc. (AQST)

Submitted NDA for Anaphylmâ„¢ (epinephrine), the first and only oral sublingual film for patients with severe allergic reactions Advancing commercial readiness

Aquestive Therapeutics (AQST) to participate in Piper Sandler Spring Biopharma Symposium on April 17, 2025. The company will conduct investor meetings d

Aquestive Therapeutics (AQST) stock gains as the company completes its marketing application for Anaphylm, an emergency treatment for allergic reactions. Read more here.

**media[582606,582607]**

Aquestive Therapeutics leverages its PharmFilm technology to develop innovative oral drug delivery systems. Find out why I'm neutral on AQST stock.

Release Date: March 06, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Aquestive Thera

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NAQST.OQ - Aquestive Therapeutics IncQ4 2024 Aquestive Therapeutics Inc Earnings CallMar 06, 20

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2024 Results Conference Call March 6, 2025 8:00 AM ETCompany ParticipantsBrian Korb - IRDan Barber - CEOErnie...

The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -35.71% and 12.11%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[558448]**

Aquestive Therapeutics Inc (AQST) is set to release its Q4 2024 earnings on March 6, 2025. The consensus estimate for Q4 2024 revenue is $13.08 million, and the

Discover Aquestive Therapeutics' (AQST) Q4 earnings results on March 5th.

Aquestive Therapeutics Inc (AQST) is set to release its Q4 2024 earnings on Mar 5, 2025. The consensus estimate for Q4 2024 revenue is $13.08 million, and the e

WARREN, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicin

**media[545447]**

**media[538616]**

Data show Anaphylm maintains consistent stability and potency under extreme temperature and real-world conditions, including heat, freezing, and water submersio

**media[531569]**